Fig 2: Changes in the expression profile of mRNAs in different breast cancer subtype samples compared to control samples obtained via RT-PCR. DRD2, dopamine receptor 2; DRD3, dopamine receptor 3; DRD5, dopamine receptor 5; TGF-β-2, transforming growth factor beta 2; CAV2, caveolin 2. Data are presented as mean ± standard deviation.

Fig 3: Venn diagram. DRD2, dopamine receptor 2; DRD3, dopamine receptor 3; DRD5, dopamine receptor 5; TGF-β-2, transforming growth factor beta 2; CAV2, caveolin 2; SLC22A1, solute carrier family 22 (organic cation transporter), member 1; CXCL12, chemokine (C-X-C motif) ligand 12; DRD1, dopamine receptor 1; NR4A2, nuclear receptor subfamily 4, group A, member 2; HRH2, histamine receptor H2; NSG1, neuron-specific gene family member 1.